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EVALUATION OF NON-DRUG TREATMENT OPTIONS FOR ALZHEIMER’S 
DISEASE 
EUN SUNG KIM 
ABSTRACT 
Alzheimer’s disease has been described long ago, yet the illness is yet to be fully 
understood. Though it is true that research and technological advancements have brought 
us closer to understanding the disease, a truly effective pharmacological cure has not 
been discovered. With no permanent cure to rely on, AD patients and their caregivers still 
go through profound struggles in navigating through life with the disease. In this thesis, 
current literature on the non-pharmacological interventions is presented and discusses the 
various options that can provide the greatest relief and reap the most health benefits for 
patients. In total, four different non-drug treatments come into discussion - exercise, 
music, diet and cognitive interventions.  
In terms of exercise, research suggests that anaerobic work may be more beneficial than 
aerobic exercises in preventing the development or progression of mild cognitive 
dementia and Alzheimer’s disease. This is mostly due to the fact that anaerobic exercises 
can shift APP processing away from the non-amyloidogenic pathway and increase BDNF 
levels to offer improved neural protection. Music therapy intervention is evaluated next. 
This unique treatment is highly valued due to its beneficial effects on AD patients’ 
emotional well-being. Music therapy can take the forms of singing in groups or as an 
individual, and it can also incorporate dancing. Not only does music promote 
neuroplasticity and neurogenesis, but it also alleviates mood, boosts confidence and 
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strengthens will. Diet is another significant component that can have an incredible impact 
on the AD patients’ wellbeing. Research reveals that diets high in saturated fatty acid 
should be avoided. On the other hand, diets mirroring the Mediterranean diet, including 
polyunsaturated fatty acids along with high amounts of vitamin C and folic acid should 
be readily consumed. Moreover, spices and herbs such as capsaicin should be used in a 
limited manner to decrease risk for AD. Finally, cognitive therapy is still a popular 
method for treating mild cognitive impairment and AD. Though cognitive improvement 
appears to be more modest, some psychostimulation programs combined with 
pharmacological treatments can play an influential role in achieving cognitive stability.  
Further research is needed in upgrading the current non-pharmacological interventions 
with an emphasis on the four treatments. These are available at an affordable cost and can 
be easily incorporated into the lifestyles of Alzheimer’s patients. 
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I. Introduction 
Background 
Alzheimer’s disease (AD) is a lethal, age-related neurodegenerative disease that is 
affecting the livelihood of millions of people both within the United States and around 
the world. The disease was identified and described in 1906 by Alois Alzheimer in 
Tubingen, Germany (21). Even after more than a century has gone by, the disease is still 
responsible for being the greatest cause of age-related neurologic impairment (26). 
Moreover, the consequences of Alzheimer’s go beyond seriously impairing the 
qualitative and quantitative aspects of the affected patient. Family members, friends, and 
caregivers also experience profound emotional suffering as they observe the unfamiliar 
changes that their loved ones go through, be they physical or emotional; some patients 
may even forget the names of their most significant family members.  
To make matters worse, providing care for a family member who is suffering from 
Alzheimer’s disease is highly expensive and difficult not only at the family level, but also 
nationally; it is financially draining for countries to take care of patients with 
Alzheimer’s. The prevalence of Alzheimer’s disease and dementia continues to increase, 
although with variability among regions and according to genetic and environmental risk 
factors such as ethnicity, sex and stress levels. Dementia is the overall term that is used to 
describe all of the symptoms that impact the brain’s memory and performance, including 
communication abilities. It has been predicted that approximately 81.1 million people 
will be diagnosed with dementia by 2040, mostly as a result of AD (4). Unfortunately, 
gaps exist in the knowledge of the disease and the underlying mechanisms of AD. 
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Without a definitive etiology and the availability of a cure, it is in the best interest of the 
patients to consider whatever forms of treatment that is available, especially the non-drug 
options. Non-drug interventions can provide relief and improve the quality and duration 
of the AD patients’ lives. It is clear that non-pharmacological treatments (with or without 
the use of pharmacological treatments) may hold great potential in aiding the patient in 
absence of an absolute cure. In order to evaluate these non-drug treatment options that are 
available to us as of now, an understanding of the major potential pathologies of AD is 
required. 
Pathogenesis 
There are several hypotheses regarding the pathogenesis of Alzheimer’s disease. 
However, these theories receive criticisms for their failure to clearly provide 
comprehensive explanations with regard to the mechanistic aspects. They also face 
criticism because the theories have found little success in creating an effective drug 
treatment. However, one of the hypotheses that receives the greatest attention is the 
Amyloid Case Hypothesis proposed by Glenner and Wong in 1984 (8). A discussion of 
the general mechanisms of the hypothesis is as follows.  
Amyloidopathy 
Although a definitive etiology of the disease has yet been elucidated yet, there are 
important pathological hallmarks to Alzheimer’s disease that provide insight and reasons 
for further investigation. First, amyloidopathy, which is described as the neuritic plaque 
formation and deposition, progresses with the formation and accumulation of the amyloid 
beta (Aβ) peptides from the proteolytic cleavage of the amyloid precursor protein, which 
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is an integral membrane protein (22). The abnormal cleavage of APP by β-secretases and 
γ-secretases produces the insoluble and sticky Aβ peptide in the extracellular regions of 
the brain that will oligomerize with other Aβ peptides (22). The deposition of the neuritic 
plaques disrupt neuronal signaling that often starts from the hippocampus, affecting 
memory, then spreading to other areas of the brain such as the cerebral cortex regions and 
the cerebellum (13). More importantly, some studies suggest that while amyloidopathy 
may be the trigger, the clinical presentation of AD symptoms is dependent on the 
hyperphosphorylation of tau proteins and the formation of the neurofibrillary tangles 
(24). 
The link between a person’s dietary intake and the risk of developing AD is also clear. A 
diet that is high in cholesterol content is influential as cholesterol is involved in the 
production of Aβ peptides (1). Note that the brain is considered the most cholesterol-rich 
organ in the human body; the brain is approximately 2.1% of the average human body 
weight, yet comprises 23% of the total body sterol content (7). Whether APP is processed 
via the amyloidogenic or the non-amyloidogenic pathway is heavily driven by the 
surrounding lipid environment. Likewise, high plasma cholesterol levels often reveal 
elevated levels of Aβ production in the brain. The direct relationship between cholesterol 
and increased Aβ production is based on the activation of β-secretases and γ-secretases 
by cholesterol, contributing to the overall amyloidopathy. Note also that the pathological 
processing of APP occurs in lipid raft membrane microdomains that are cholesterol 
enriched, and hypercholesterolemia creates a favorable cellular environment for amyloid 
plaque formation (7). 
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Figure 1. Amyloidopathy. Diffuse deposits of amyloid β protein in the cerebellum of a 
patient 68 years of age. Abnormal processing of APP that leads to build up of neuritic 
plaque stained dark in the image. Figure taken from Maślińska et al., 2017. 
 
 
 
 
Figure 2. Amyloidopathy. “Stick-like” shape of amyloid β deposit in the cerebellum of a 
patient 72 years of age. The amyloid β deposited in a rather specific region in the brain 
stained in dark. Figure taken from Maślińska et al., 2017. 
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Fig. 3. Amyloidogenic and Non-amyloidogenic processing of APP. The left side of the 
figure illustrate the amyloidogenic processing of APP by β-secretases and γ-secretases. 
The right side of the figure shows the non-amyloidogenic processing of APP by α -
secretases and γ-secretases. The amyloidogenic pathway results in pathological changes. 
Among other abnormal alterations, the amyloid plaque build is believed to responsible 
for the progressive cognitive impairment. The oligomer Aβ is insoluble and sticky 
whereas the products of the pathway on the right are soluble and do not self-aggregate. 
Also, note that because of the physical characteristics of amyloid beta, the plaque often 
takes up the configuration of a β-pleated sheet. Figure taken from Sanabria-Castro et al., 
2017.  
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It is also hypothesized that these extracellular Aβ peptides not only deposit extracellularly 
around the neurons, but also deposit extracellularly around cerebral vessels. This 
deposition leads to a pathological condition classified as cerebral amyloid angiopathy 
(CAA). The progressive development of CAA may lead to cerebral infarcts as well as 
intracerebral hemorrhage, an extremely dangerous condition for the brain that often 
exacerbates other pathological conditions (23). The build-up of insoluble amyloid beta 
peptides on the vasculature impairs the overall cerebrovascular integrity, and the lobar 
intracerebral vessels are noted to be highly vulnerable. This condition is also untreatable 
by current pharmacological interventions. CAA deteriorates the homeostatic capability of 
a blood vessel by diminishing the ability to dilate or constrict in response to physiological 
stimulation, rendering the vessel vulnerable to ischemic damage (20). CAA is also 
regarded as another hallmark of Alzheimer’s disease; however, it is more often 
categorized under the condition of amyloidopathy. 
 
Figure 4. Cerebral Small Vessel Amyloidopathy. Left is microscopic fluorescent 
images of Aβ immunostaining (red) in the hippocampus of the AD symptom mice. Most 
of the Aβ accumulation is adjacent to cerebral small vessels. Right image showing higher 
magnification of Aβ accumulating vessels. Figure taken from Saito et al., 2017. 
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Tauopathy 
Another major hallmark of Alzheimer’s disease is the associated tauopathy. Research has 
demonstrated that the initial amyloidopathy inadequately explains the complete 
etiopathogenesis of AD (21). The abnormality that occurs with the tau protein is believed 
to be a secondary event induced by the initial neuritic plaque buildup (21). In contrast to 
the extracellular amyloidopathy that occurs around the neurons and cerebral vessels, 
tauopathy occurs intracellularly, causing equally devastating effects. The tau protein is a 
soluble protein that has functional and structural importance for the neuronal 
microtubules. An improper management or production of tau proteins can compromise 
axonal transport, neuronal growth, and structural integrity (21). The tau pathology is 
characterized by the hyperphosphorylation of the tau protein that is related to the 
maintenance of the structure and function of the microtubules supporting the neuron.  
More specifically, the tau protein is a neuronal cytoskeletal protein that supports the 
polymerization of microtubules and stabilizes the final polymer (27). The increased 
phosphorylation of the tau proteins leads to a pathologic self-accumulation of the proteins 
that consequently result in what is known as neurofibrillary tangles (NFT). The resulting 
destabilization of the neuronal cytoskeletal network promotes neuronal impairment by 
leading to malfunction of axonal transport (27). Rather than associating itself with the 
microtubules within the neurons, the tau protein self-accumulation leads to the 
fibrillization; as expected, the hyperphosphorylated NFT appears to accumulate in the 
hippocampus first and then invade gradually other regions of the brain such as the 
amygdala and cortical areas (21).  
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Figure 5. Tauopathy in Hippocampus and Cortex. Immunostaining of tau fragments in 
brain sections from the hippocampus and the cortex of subjects with AD is shown on the 
top left and bottom left images. The figure shows elevated levels of tau fragments that is 
darkly stained in the AD patient compared to the top right and bottom right images at 
significant levels. The AD patient is demonstrating greater neurofibrillary and tau 
pathology compared to a normal patient. Figure taken from Zhang et al., 2014. 
Oxidative Stress 
While the major pathological hallmarks of Alzheimer’s disease are the amyloid plaque 
deposition and the neurofibrillary tangles, the AD brain often exhibits elevated levels of 
oxidative stress and notable levels of neural inflammation (1). Oxidative stress is 
influential in the neurodegenerative progression as it is linked to neuronal apoptosis. The 
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increased levels of reactive oxygen species in the AD brain are responsible for the cell 
damage. Therefore, the progression of AD can be tracked by the similar degree of free 
radial damage accumulation. It is, however, believed that the discussed pathological 
hallmarks of AD are not mutually exclusive. It has been shown in studies that amyloid 
beta deposition may facilitate the production of reactive oxygen species in the brain. 
Some studies claim that oxidative stress may be the initial event that leads to the amyloid 
beta buildup. More importantly, high levels of oxidative stress are harmful to the 
neuronal mitochondria function and structure. The resulting mitochondrial dysfunction is 
responsible for worsening the stress placed by the reactive species. As a result, what 
occurs is the activation of caspase enzymes and subsequent apoptosis of brain cells (21). 
Vascular Pathology 
Another hallmark of AD that is receiving greater interest in the recent years is the 
associated vascular pathology that often accompanies cognitive decline in AD patients. 
These pathological changes associated with vasculatures are distinct from the cerebral 
amyloid angiopathy that results from amyloid beta deposition around the small cerebral 
vessels. Rather, the original presence of a vascular disease and history of a vascular risk 
factors (VRF) may highly predispose an individual to mild cognitive impairment and AD 
development. Studies demonstrate that risk factors such as vascular injuries, 
hypertension, and cerebral hypoperfusion in certain brain regions have links to 
hippocampal atrophy (note that hypertension is associated with neural hypoperfusion). 
Hypertension may also lead to elevated levels of reactive oxygen species and brain 
mitochondrial dysfunction. Hence, the hypertensive environment creates a neuronal 
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energy crisis, neuronal damage, apoptosis, neurodegeneration, and widespread neural 
inflammation, contributing to the progression or development of AD (8). Some research 
even points to the theory that the progression of sporadic AD is directly related to 
neurodegenerative processes of the vascular pathology more than amyloidogenic 
processes (8). Fortunately, there is evidence that AD risks associated with the vascular 
pathologies are reversible, which is important as dietary and exercise interventions may 
play influential roles in managing vascular health. 
Symptoms and Brain Regions Affected 
The symptoms of the neurodegenerative disease include dementia, mood disorders, 
general disorientation, and language problems among others that appear to worsen over 
time (21). Furthermore, Alzheimer’s disease is paralleled with neurodegeneration and 
structural atrophy of other brain regions. For example, AD has been associated with 
severe atrophy in frontal, prefrontal, temporal, medial-temporal and limbic cortices. Mild 
cognitive impairment (MCI) is the earliest stage showing neurodegenerative symptoms 
that may further progress to AD. At the MCI level, the medial temporal and temporal 
cortices reveal noticeable atrophy.  
Symptoms, however, go beyond the cognitive deficits and structural changes and atrophy. 
In everyday life, patients may demonstrate psychological and social changes, which 
complicate the ability of family members and caregivers to provide proper care. These 
changes may include aggression, anxiety, hallucinations, and culturally improper 
behaviors. Patients may behave unlike themselves, which may cause embarrassment, 
shame, confusion and anger among many other emotions on the part of the people taking 
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care of the patient. As previously mentioned, this diminishes the quality of life for both 
the patient and for family and friends (18). Currently, there are also limited benefits of 
pharmaceutical treatments for managing such psychological, social and behavioral 
symptoms associated with mild cognitive impairment and AD (18).  
 
Figure 6. Regions of Brain Affected by AD. Alzheimer’s disease (AD) patients show 
severe cortical atrophy in selective regions of the brain. The figure shows common areas 
that are affected by AD such as the frontal and prefrontal cortex. Also, the temporal, 
medial-temporal and limbic areas are affected as well. Specifically, neural structures 
associated with these regions include the thalamus, basal ganglia, cingulate cortex, 
fornix, hypothalamus, amygdala, hippocampus and entorhinal cortex. Pfc: Prefrontal 
cortex; Cc: Cingulate cortex; Ec: Entorhinal cortex; T: Thalamus; hp: Hypothalamus; a: 
Amygdala; h: Hippocampus. Figure taken from Hess and Smart, 2017.  
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Types of Alzheimer’s Disease 
Alzheimer’s disease can be classified as sporadic – also known as late-onset – or familial 
– also called early onset – types. The sporadic type comprises of the majority of the 
disease cases and involves both genetic and environmental risk factors. On the other 
hand, the familial type constitutes less than 10% of found cases and has a dominantly 
genetic risk factor. In either forms of AD, apoliprotein E (apoE) ε4 allele has shown an 
association with the disease by potentially leading to a lipid transport system failure. 
(Note that the apoE ε4 protein product is the principal cholesterol transporter in the 
brain). This failure, in turn, can lead to the pathologies associated with the amyloidopathy 
and tauopathy due to the uncontrolled cholesterol management in the brain (24). As 
previously noted, cholesterol levels can directly influence the manner by which APP is 
processed. This genetic factor has been hypothesized to be associated with the failure of 
the lipid transport system although the complete mechanism for the associations has not 
been fully discovered (24). More importantly, sporadic AD is considered to be a 
multifactorial disease with both genetic and environment contributions, further 
complicating the complete understanding of the disease and its underlying mechanisms 
(24). Likewise, both sporadic and familial AD pathologies have demonstrated formation 
and deposition of neurofibrillary tangles and amyloid plaque depositions. Currently, there 
is still no cure for either forms of Alzheimer’s (2,14).  
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Current Drug Treatment Options  
Current pharmacological treatments available for Alzheimer’s are not complete 
treatments. In reality, the treatments available are only able to temporarily delay 
symptom development or admission to care facilities (11). Cholinesterase inhibitors and 
memantine are a few of the drug treatments offering benefits that are clinically 
significant, though with much room for improvement (10). Moreover, the drug treatments 
trials are conducted mainly on animal models and have obstacles translating over to 
actual human trials and experiences. Thus, it is extremely important to study the potential 
effects of non-drug therapies that may benefit Alzheimer’s patients (1,12). With the 
understanding that treatment does not only come solely from pharmaceutical options 
only, there is strong evidence that non-pharmaceutical options can provide noticeable and 
greater relief. They may even delay symptoms at a more significant rate and magnitude 
than their drug counterparts. 
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II. Exercise Therapy Interventions 
Exercise and Role of BDNF  
The progression of Alzheimer’s disease continues when APP is processed in a manner 
that is amyloidogenic rather than non-amyloidogenic. The non-amyloidogenic APP 
processing occurs via the cleavage of the polymer by α-secretases and γ-secretases rather 
than by γ-secretases with β-secretases which leads to the neurotoxic Aβ formation and 
deposition. It is widely accepted that when APP is processed with α-secretase instead the 
resulting peptide is neuroprotective and slows the neurodegenerative progression by 
producing non-amyloidogenic α-secretase-derived secreted form of APP (sAPPα) (17). 
Several findings agree that exercise is an extremely effective and inexpensive non-drug 
intervention for AD patients (10). Exercise does not only reduce risk for AD, but also 
reduces the harmful levels of non-amyloidogenic APP processing via an effect mediated 
by brain-derived neurotrophic factor (BNDF) (17). The up-regulation of BNDF has been 
associated with several of the benefits. These benefits include increased neuroplasticity, 
resistance to cellular stress, neural growth, and neural protection while preventing brain 
degeneration and atrophy. In addition, findings in mouse models suggest a potential 
mechanism of how exercise may significantly slow AD progression. Time and time 
again, exercise has been demonstrated to increase levels of BDNF, which have been 
associated with increased levels of working α-secretase, undertaking the non-
amyloidogenic pathway instead (17). The findings from the mouse model translated to 
similar benefits in human neural cells cultured with BDNF, which showed the expected 
finding that the pathologic amyloid beta peptides that were released into the medium 
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were reduced at a statistically significant level as shown in Figure 7 (17). Note that Aβ40 
and Aβ42 are the products that are liberated from the amyloidogenic processing of APP. 
 
Figure 7. Exercise shifts APP processing towards the non-amyloidogenic pathway. 
The top left figure shows that exercise leads to a reduction in hippocampal Aβ40 levels in 
mice. Top right image shows a similar finding where exercise resulted in hippocampal 
Aβ42 reduction at statistically significant levels. Bottom left image reveals that exercise 
had a significant influence on increasing the levels of sAPPa in exercising mice. Bottom 
right image shows increased levels of hippocampal BDNF in mice that exercised 
compared to control mice not exercising. Note that hippocampal levels of Aβ40, Aβ42, 
and BDNF were measured by ELISA. Figure taken from Nigam et al., 2017. 
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Figure 8. BDNF and reduced Aβ released from human neural cells in an α- 
secretase-dependent manner. (A) and (B) reveal that BDNF inversely affected levels of 
Aβ40 and Aβ42, respectively. In the same images, culturing human neural cells in α-
secretase inhibitor (α- secr.Inh.) resulted in increased amyloidogenic processing of APP 
as evidence by increased Aβ40 and Aβ42 levels in A and B, respectively. (C) shows 
increased sAPPα, neuroprotective proteolytic product of APP at significant level when 
cells were cultured in BDNF during a 3-day incubation period. Figure taken from Nigam 
et al., 2017. 
Data also suggests that BDNF can promote a beneficial redistribution of α-secretase from 
the cell surface to the inside of the neurons where the enzyme activates the non-
amyloidogenic APP processing pathway (17). 
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Progressive Resistance Training and Cognition 
Older patients who underwent progressive resistance training (PRT) have demonstrated 
significant improvements in cognitive function more than aerobic exercises measured by 
percent change in VO2peak. There is statistically significant evidence that high-intensity 
anabolic strength training does indeed harbor real cognitive benefits, which is very good 
news for Alzheimer’s patients or those who are worried about being affected by the 
disease and are looking for preventative methods. More specifically, findings suggest that 
it is the skeletal muscle work that accounts for the cognitive benefits of PRT; VO2peak 
failed to show noticeable changes in measures of cognition. The findings can be seen in 
Figure 9 below and demonstrate the individual benefits of strength training on the 
Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-Cog), cognitive 
global, and cognitive executive domains. It is important to note that increases in lower 
body strength were linked with increased improvements on measures of cognition while 
lower and whole-body strength increases showed little association (14). However, lower 
body strength gains were not associated with gains in the executive domain. Further 
research is required to unravel the complicated underlying mechanisms linking anabolic 
exercise to cognitive functional improvements. 
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Figure 9. Lower body 
strength gains and global 
and executive cognitive 
domain benefits.  
(A) shows lower body 
strength gains significantly 
mediated the effect of PRT 
on ADAS-Cog score. (B) 
Gains in lower body strength 
significantly mediated the 
effect of PRT on global 
cognitive domain. (C) Gains 
in lower body strength did no 
mediate the effects of PRT of 
executive cognitive domain 
at significant levels. 
Solid lines represent direct 
relationships. Dashed lines 
represent indirect 
relationships. 
In (A), (B), and (C), the total 
effect of PRT on cognitive 
function is shown at the top. 
The bottom of each image 
shows both direct and 
indirect effects with respect 
to lower body strength gains. 
Figure taken from Mavros et 
al., 2016. 
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It is hypothesized that the effect of anabolic exercise may be also linked to a rise in 
BDNF and a subsequent rise in α-secretase levels, diminishing the progression of the 
amyloidogenic pathway in older adults with mild cognitive impairment or with 
Alzheimer’s disease. Another theory on how PRT may provide improved cognition is by 
increasing levels of insulin-like growth factor 1 (IGF-1). Studies have shown that low 
levels of IGF-1 were associated with cognitive dysfunction and dementia in older 
patients. A 24-week PRT program has demonstrated increased production of IGF-1 that 
was paralleled by similar levels of cognitive improvements (14). Additionally, although 
studies provided results that PRT also increased VO2peak, there was no association 
between VO2peak improvements and cognition improvements (14). Older patients may be 
less inclined to strength exercises as they grow weaker with age and favor less strenuous 
aerobic exercises. However, anabolic exercises provide clinically relevant health benefits 
beyond simple physical health gains for the elderly with mild cognitive impairment or 
AD (14).  
Isometric Exercise Training and Vascular Risk Management 
Physical exercise in the form of isometric exercise training (IET) may also effectively 
slow down the development of dementia and cognitive impairment associated with AD 
patients (5,8,9). Additionally, isometric exercises have been shown to display benefits at 
the preclinical stage by managing vascular risk factors (VRF). VRFs are especially 
important to manage well before onset of any disease because they have been 
demonstrated to lead to progressive and chronic neurodegeneration (8). Vascular risk 
factors include hypertension, hyperlipidemia, and cerebrovascular disease that may lead 
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to cerebral hypoperfusion and neuronal dysfunction. All of this can then lead to the 
development of AD. Vascular risk factors are considered by some studies as another 
means of pathogenesis of AD that is non-amyloidogenic in its initiation. It is suggested 
that neurodegeneration may start as a systemic and neural vascular deterioration that 
leads to increased Aβ production and neuronal dysfunction. Moreover, compromised 
neurovasculature leads to neuronal dysfunction and injury associated with dementia as 
shown in Figure 10. 
Because the majority of neurodegeneration associated with AD is strongly associated 
with vascular risk factors, research on this association has demonstrated that isometric 
exercises can be beneficial for AD patients by controlling VRF. The exercises are 
suggested to slow down the atrophy of the neural regions associated with AD by 
improving the vascular integrity and managing blood pressures in hypertensive patients 
(8). Data suggests that these improvements coming from the aforementioned exercises 
are significant when compared to the improvements gained from a dynamic series of 
aerobic and resistance exercises. This study leads to a conclusion slightly different from 
the studies discussed previously, where resistance exercises led to significant cognitive 
improvements. However, there is an agreement that some form of strength exercise is 
more beneficial than performing aerobic training alone (9). 
Mild cognitive impairment is often the earliest symptom stage revealing the possible 
onset of the Alzheimer’s disease. It is at this stage where earliest forms of interventions 
with non-drug therapy options may reap the most benefit and aid the patient significantly. 
Although aerobic cardiovascular exercises have been the preferred method for 
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maintaining a healthy blood pressure, isometric exercises may be a better option as they 
have been shown to better improve resting systolic and DBPs in older men and women 
with high or normal blood pressure. Essentially, the findings suggest that IET promotes 
greater anti-hypertensive effects such as improved vascular reparations and cerebral 
blood flow. Additionally, extra benefits such as reduced chronic low grade inflammation 
combined with vascular improvements may be effective therapeutic interventions against 
MCI and AD (8).  
On the mechanistic level, vascular risk factors are believed to compromise nutrient 
delivery to the brain, the blood brain barrier integrity, and the clearance of toxic 
metabolites in the brain as shown in Figure 10. Note that vascular functional failure is 
associated with the decreased clearance of pathologic amyloid beta peptides and 
contributes to worsening amyloidopathy in the brain. The dysfunction of the neural 
vasculature signifies the loss of homeostatic capability of the brain and can lead to cell 
damage, programmed cell death, and widespread neurodegeneration (14). 
Finally, when considering the results that suggest that such exercise programs can create 
an anti-inflammatory environment and manage a patient’s cerebrovascular health, 
muscular exercise variations should be recommended as an effective non-
pharmacological intervention for Alzheimer’s disease.  
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Figure 10. Vascular risk factors linked to dementia. VRF include hypertension, 
atherosclerosis, hyperlipidemia and cerebrovascular disease. These factors are linked to 
cognitive disorders. The presence of VRFs is believed inhibit both the delivery of 
nutrients to the brain and the clearance of toxic metabolites, compromise the integrity of 
the blood brain barrier (BBB). The culmination of these effects promote the accumulation 
and development of the major pathological hallmarks associated with AD. Note that 
vascular dementia is not accompanied by these same hallmark neurodegenerative 
processes. However, for both vascular dementia and AD, the abnormal status of the 
cerebral vasculature is believed to promote cellular disruption, cell death and cognitive 
impairment ultimately resulting in dementia. Figure taken from Hess and Smart, 2017. 
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III. Music Therapy Interventions 
Alzheimer’s patients undergo deterioration of psychological and mental functioning. It is 
a widely held belief that music therapies, especially singing individually or in groups 
such as choirs can be a highly effective method of psychosocial intervention and to 
manage symptom in all AD patients. Ultimately, the lack of an effective drug treatment 
for alleviating such psychosocial symptoms places more of an impetus on doctors and 
families of patients to seek beneficial effects from such non-pharmacological 
interventions. 
Music therapy is a valid form of treatment for Alzheimer’s patients dealing with many 
forms of dementia. In 2003, the Alzheimer’s Society established Singing for the Brain, a 
program where dementia patients were encouraged to learn the lyrics and melodies of 
new songs and practice them together in groups. The Singing for Brain study found that 
qualitative aspects of the patients’ lives as well as those of the caregivers showed drastic 
improvements. A thematic analysis of the patients’ accounts of the experience revealed 
increased feelings of social inclusion and support, a sense of shared experiences, a 
positive impact on relationships, a positive impact on memory, lifted spirits, and 
acceptance of the diagnosis of the AD (18). It is also believed that singing songs and 
making music in a group rather alone may be potentially more powerful therapeutically 
because it minimizes the negative feelings of isolation. Singing in groups is beneficial for 
those who do not even have AD, and thus undoubtedly brings drastic benefits for AD 
patients.  
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In addition, the findings suggest that singing is an effective therapy because it can 
stimulate processes and reminiscence. Singing also provides patients with confidence and 
the ability to manage anxiety common to dementia patients. It helps patients to realize 
that parts of their cognitions still functions as they successfully remember the lyrics and 
melodies. This build-up of confidence as they recall parts of the lyrics and memories, 
boost their mood and strengthens their will to fight the disease. Patients and caregivers 
were surprised to find that patients often did not have to rely on the sheet music to 
remember the lyrics or the melodies as well (18). This may be due to the hypothesis that 
the memory of singing lays less in the brain but more in the muscles of the mouth, 
diaphragm, vocal chords and all other body parts associated with producing sound.  
Furthermore, it is believed that it is the emotional aspect provided by music that 
stimulates faster recall and improved cognitive functioning. Also, it is noteworthy to 
notice that the benefits of music therapy went beyond simply improving memory of the 
patients. Both patients and caregivers recall that they were better able to manage their 
emotions by finding an outlet for stress, a place and time where they can relieve their 
negative emotions and create positive ones. While specific quantitative measurements of 
the improvements are not available, qualitative improvements are rather significant.  
Music therapy is inexpensive, yet its importance and effectiveness as an interventional 
method is invaluable. Many findings suggest that singing is especially useful because of 
the absence of side effects after therapy and the convenience of providing the therapy (5). 
All that is needed is a group of willing participants, some music and the ability to make 
sound with the vocal chords. Additional data also suggests that simply listening to music 
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may also have significant improvements for AD patients. It was found that listening to 
classical music greatly promoted the ability to complete spatial-temporal tasks. 
Improvements in familiarity and preference for patients were also suggested to be 
improved in studies as a result of music. Stabilization in self-consciousness of mild or 
moderate AD patients was observed as well (5). 
Moreover, combining music with expressive activities such dancing is a beneficial 
intervention as well. The results of such intervention demonstrated that a combination of 
music with dancing movements of the body could alleviate both the psychosocial 
symptoms and cognitive status of AD patients (5). 
Potential Mechanisms of Music Interventions  
There are four main theories describing the potential mechanism by which music therapy 
positively benefits AD patients. The neuroplasticity mechanisms suggest a that music 
promotes neuroplasticity. Studies have discovered using function Magnetic Resonance 
Imaging (fMRI) that singing songs increased neural activity in the right angular gyrus 
and the left lingual gyrus indicating that music may play an important role in promoting 
neuroplasticity (5). Another research has indicated a second mechanism that would 
consist in improving the growth and maintenance of neuronal circuits. The data suggests 
that listening to music could increase endogenous steroid hormone levels that is linked to 
higher levels of neurogenesis, regeneration, and neuronal repair (5). The third 
neuroendocrine mechanism suggests that Alzheimer’s patients who received a month 
long musical intervention showed noticeable increase in 17β-estradiol and testosterone 
levels. Research has demonstrated that these hormones may play a significant role in 
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slowing the progression of the disease (5). Studies where these hormones were injected 
showed negative side effects while a natural hormonal boost from music therapy showed 
an absence of any side effects previously observed by artificial hormonal injections. 
Ultimately, the last mechanism suggests that music has an emotional component that may 
influence an AD patient’s cognition; this is the neuropsychiatric mechanism.  Listening to 
music showed that emotions associated with anxiety were decreased while 
autobiographic memory of AD patients improved. It is believed that, rather than the 
music itself, the emotional aspect is what stimulated the semantic memory (5). 
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IV. Diet Therapy Interventions 
Diet therapies are also of interest to researchers trying to combat the various symptoms 
associated with AD. Currently, the high-fat Western diet has been associated with 
significantly increasing the rate of AD progression and susceptibility independently of 
any metabolic disorders. The Western diet is notably high in saturated fatty acid content 
associated with cognitive deterioration; research indicates that 4 to 6 years of high 
saturated fatty acid content in diet will highly predispose older adults to developing mild 
cognitive impairment or AD (12).  
Although the precise mechanisms illustrating how high-fat diets affect AD progression is 
yet to be described, such diets were associated with exacerbated amyloidopathy and 
hippocampal oxidative stress in mice with overexpression of human amyloid precursor 
protein and familial AD mutations (12). These mice are classified as the 5XFAD mice. 
Although there have not been any data showing that high-fat negatively induces AD in 
mice, research indicates that choosing a healthier diet may be an effective management 
for patients already diagnosed with Alzheimer’s.  
Data suggests that the effects of a high-fat diet are mediated by increasing cerebral 
amyloid angiopathy potentially by decreasing levels of BDNF (12). Western blot analysis 
revealed that 5XFAD mice given high-fat diets had a significant decrease in BDNF levels 
as shown in Figure 11. BDNF, as previously discussed, is associated with increased 
neuroplasticity and cellular stress resistance, preventing neurodegeneration and brain 
atrophy. The same study reported that putting a 5XFAD mice on a high-fat diet decreased 
levels of cerebral occludin. Cerebral occludin has an important structural role in 
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maintaining the structural and function integrity of tight junctions. Decreased levels of 
the protein in the brain may indicate that the blood brain barrier may also be 
compromised structurally, which would contribute to the the progression of cognitive 
decline. However, it is important to note that a healthy wild type mouse would not show 
diminished cerebral occludin levels even on a high-fat diet (12). 
 
 
 
Figure 11.  Effects of High-Fat Diet on BDNF and Occludin. The figure shows a 
Western blot analysis of occludin and BDNF. Note in the right side of the figure, the 
5XFAD mice on a high-fat diet shows decreased levels of both BDNF and cerebral 
occludin compared to mice on a control diet. The wild-type mice on either a control of a 
high-fat diet failed to show significant reductions in cerebral BDNF and occludin levels. 
5X: 5XFAD mice; BDNF: brain-derived neurotrophic factor; CD: control diet; HD: high-
fat diet; WT: wild-type mice. Figure taken from Lin et al., 2016.  
A diet with a high saturated fatty acid content shows that cerebral oxidative stress may be 
increased. Literature shows that an unhealthy diet can significantly raise super oxide 
levels in the hippocampus. Similarly, just as the influence on BDNF and occludin, a 
mouse without AD expression was shown to be unaffected by a fatty diet treatment (12).  
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Results show that 5XFAD mice placed on high-fat diet also showed increased levels of 
Aβ formation and deposition in the cerebral hippocampal or parenchymal vascular 
regions compared to 5XFAD mice placed on a normal diet as shown in Figure 12. 
Additionally, the same mice on the fattier diet also demonstrated significantly less 
collagen IV positive areas that indicates compromised vessel basal lamina and 
contribution to the worsening angiopathy and AD pathological symptoms. 
 
Figure 12. Quantification of Aβ Deposits in Cerebral Vasculature. (A) shows 
immunostaining of beta amyloid deposits and collagen IV in the middle cerebral artery. 
In (A), 5XFAD mice on a high-fat diet showed less staining of the vessel basal lamina, 
indicating progressive structural or function compromise of the cerebral vasculatures. (B) 
shows that a high-fat diet significantly increased amyloid deposits in the cortical artery. 
Note that in (B) wild-type mice showed no increase in amyloid deposits on either a 
control or high-fat diet. HD: high-fat diet; CD: control diet; 5X: 5XFAD mice; WT: wild-
type mice. Figure taken from Lin et al., 2016. 
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Healthier Diet 
Research points to a rather strong association between an unhealthy diet or poor 
cardiovascular health (common with aging) and compromised cognition in the elderly 
population. Moreover, studies also point out that opting to switch to a healthier diet can 
indeed have benefits for patients who have AD or are at the risk of AD. The 
Mediterranean diet (MD, which is highly nutritious, is considered to be one of the 
world’s healthiest diets. There are variations to the diet’s specific composition, but is 
healthy as it has high content of fruits, vegetables, fish, eggs, monounsaturated fatty acids, 
olive oil content, anti-oxidants, and fiber (3). It is also low in foods generally considered 
unhealthier such as meats, poultry, and dairy. Studies suggest that such diets lower the 
risk for cardiovascular diseases and inflammatory responses, which are considered to be 
linked to neurodegeneration and Alzheimer’s dementia.  
Mediterranean diet may lead to better mental health for older patients due to a high 
content in vitamins, folic acid, and omega-3 fatty acids. Further studies are required to 
determine which specific nutritional components help lower AD risk. Additionally, the 
MD diet differs from the common Western diet which is associated with higher saturated 
fat and sugar content (16). It is hypothesized that the benefits also involve an overall anti-
inflammatory and anti-oxidative effect that contributes to promoting better cardiovascular 
and cerebrovascular health (3). Take note of the dietary options that are considered to 
create a low risk for the Alzheimer’s disease and the food options that are high risk in 
Figure 13. 
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Figure 13. Dietary options and association with Alzheimer’s risk. Figure taken from 
Abate et al., 2017.  
 
Obesity and Alzheimer’s Disease 
Studies have also pinpointed how obesity can accelerate the progression of AD associated 
with apolipoprotein E (apoE) ε4 allele (19). As discussed previously, the ε4 allele has the 
strongest genetic association with sporadic AD. Studies indicate that obesity is worsening 
AD pathology for models with only the ε4 allele and not models with the ε3 allele (16). 
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This suggests that there is a rather specific gene-environment relationship in Alzheimer’s 
disease. While the apoE ε4 genotype does predispose a person more strongly to AD 
pathology, it is important to note that obesity can further accelerate the disease 
progression. Data suggests that obesity contributes to one of the highest levels of amyloid 
plaques and neurofibrillary tangles in AD patients (16). The precise mechanism linking 
the apoE ε4 allele and obesity remains unknown. However, it is suspected that metabolic 
impairments associated with obesity may contribute to higher level of neural 
inflammation in the hippocampus, which is widely associated with notable AD risk and 
development of AD symptoms. It is thought that the systematic and neural inflammation 
linked with obesity contributes to cell damage and death of microglia and neurons (16). 
Additionally, obesity can create a hypertensive environment, which by itself is strongly 
associated with the development and progression of the disease. 
Vitamins on Plaque and Vascular Management 
The theory that pathological aging is driven by gradual buildup of free radicals and 
increasing oxidative stress has spurred interest in the approach of managing the aging 
body with anti-oxidants such as ascorbic acid, commonly known as vitamin C, may be 
beneficial (15). As a reducing agent, vitamin C can lower levels of free radicals in the 
human body, especially lessening the oxidative stress on the tissues of the central nervous 
system (CNS). Essentially, ascorbic acid is believed to offer neural protection for AD 
patients by directly lowering the CNS levels of oxidative stress. Additionally, vitamin C 
is can also manage neural inflammation in AD patients as well as reducing the levels of 
amyloid plaque deposition as shown in 5XFAD mouse models (15). When the burden 
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from amyloidopathy is lessened, vascular functioning is restored, providing stronger 
means for defending against AD pathogenesis. This vitamin has been associated with 
promoting improved cardiovascular health and vascular integrity, providing an 
intervention especially at level of AD pathogenesis. Essentially, vitamin C offers various 
health benefits for the brain through a numerous means that require further investigation 
of its role in AD risk management. 
On the other hand, research has found that supplements such as vitamin E neither reduce 
MCI and AD risk nor improve brain functions in AD patients with dementia (6). 
However, no side effects have been associated with vitamin E intake, so further 
investigation may be necessary before caregivers deliberately decide to incorporate 
vitamin E in the AD patient’s diet (6). More importantly, research fails to provide any 
evidence of significant benefits of vitamin E on cognition, especially on learning and 
memory. Further research is required to discover other nutritional supplements that may 
have noticeable benefits alone or together with drug treatments on central nervous system 
health. 
Other Nutritional Management of Alzheimer’s Disease 
While the previously mentioned forms of dietary interventions focus on improving the 
cardiovascular health by targeting the issues of amyloidopathy and oxidative stress 
accumulation, folic acid has been shown to provide a rather direct reduction in 
hyperphosphorylation levels of the tau proteins. (Tau hyperphosphorylation and 
intracellular neurofibrillary tangles are hallmarks of the disease as described previously). 
Tau proteins that are abnormally phosphorylated can benefit from the action of certain 
 34 
protein phosphatases. Specifically, protein phosphatase 2A (PP2A) is a serine/threonine 
phosphatase that was shown to reduce the number of tau protein phosphorylation. The 
activity of this protein can be increased and decreased by methylation and demethylation, 
respectively. Folic acid inhibits the demethylation of PP2A and upregulates the 
phosphatase activity, lowering the number of phosphate groups attached to the subunits 
of the tau protein (27). Folic acid can maintain proper activity levels of PP2A to prevent 
formation and deposition of NFT and amyloid beta plaques. A mouse model 
demonstrated that a lack of folic acid in the diet could lead to PP2A dysfunction by the 
lack of methylation of the protein phosphatase. Note too that folic acid was only 
associated with the increase in the activity levels rather than leading to more PP2A to be 
expressed entirely (27).  
Ultimately, folic acid in an individual’s diet may be essential to manage the progression 
of the disease in AD patients by allowing the patient to keep levels of tau protein 
phosphorylation in check, targeting a significant pathological hallmark of AD.  
Along with preventative effects of folic acid on the issue of hyperphosphorylation, intake 
of dietary capsaicin may also have similar benefits. Capsaicin produces a spicy 
stimulation that may cause reduction in food consumption, which may reduce total 
caloric intake and obesity risk. However, rather than the effect of consuming less total 
calories due to its taste sensation, it appears that capsaicin itself may also cause a direct 
reduction in hyperphosphorylation of tau protein. The mechanisms for its effect are still 
unclear, but researchers hypothesize that capsaicin may restore the brain insulin signaling 
pathway that in turn prevents the abnormal hyperphosphorylation of tau (24).  
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V. Cognitive Therapy Interventions 
Another form of non-pharmacological intervention for Alzheimer’s disease is cognitive 
therapy (CT) or cognitive training. CT aims to improve cognition through a systematic 
and structured set of tasks that train a patient’s memory, attention, and language abilities. 
Additionally, such therapeutical interventions aim to improve mood, self-esteem, and 
quality of the patients’ and the caregivers’ lives.  
The subsets of CT include reminiscence therapy and individualized cognitive 
rehabilitation therapy. The reminiscence therapy is structured to focus on focusing on 
personal themes such as memories relevant to one’s life events while the general 
cognitive therapy focuses on training attention, language, and executive functions. On the 
other hand, individualized cognitive rehabilitation therapy exclusively consists in training 
memory related to meaningful activities such as functional activities relevant to daily 
living. While there is controversy on whether general CT offers real, lasting results for 
AD and dementia patients, several literature reports claim some by patients who undergo 
specific forms of CT. Additionally, just as with the previously discussed non-
pharmacological interventions such as exercise, music, and healthier diet, existing 
research suggests an absence of side effects (2).  
It is important to note that results were less significant when patients received cognitive 
therapy or reminiscence therapy in groups. Results were more significant for a group of 
patients undergoing a more personal and specialized treatment type known individualized 
cognitive rehabilitation therapy as seen in Figure 14. The data suggests that certain forms 
of CT can indeed provide improvement functional cognition. More importantly, as 
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measured in Figure 14, a greater delay in the beginnings of institutionalization was 
shown for AD patients in the group that received individualized cognitive rehabilitation 
therapy exists. However, these benefits were rather moderate. Although CT has become 
relatively popular recently, clinical trials did not provide definitive evidence for its 
efficacy. These forms of therapy should be considered, but further research is required to 
improve current forms of cognitive therapies to better provide health benefits for AD 
patients (2). 
 
Figure 14. Therapy Type and Delay of Institutionalization. The figure shows that 
groups of patients that participated in the individualized cognitive rehabilitation program 
showed the greatest delay of institutionalization compared to the other groups. Cognitive 
therapy may provide important benefits for older adults as the individualized cognitive 
rehabilitation therapy group showed delayed institutionalization of about 6 months, 
indicating clinically significant benefits that can be gained through such programs. Figure 
taken from Amieva et al., 2015. 
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Integrated Psychostimulation Program with Drug Options 
Studies suggest that providing cognitive therapy in combination with pharmacological 
treatment may have synergistic effects. Integrated Psychostimulation Programs (IPP) 
provide AD patients who are already on a pharmacological treatment, specifically 
acetylcholinesterase inhibitors, with cognitive stimulation program. IPP is founded upon 
the idea that a combination of pharmacological and non-pharmacological interventions 
can produce the most well-rounded improvement for AD patients. The IPP provides 
stimulation for reasoning, concentration, memory, reminiscence, validation, and reality 
orientation. IPP can also utilize music therapy interventions or other programs along with 
pharmacological options. The goal of the program is to achieve an improved 
neuroplasticity response in the AD patient’s brain. Patients who underwent this study 
found that they were able to maintain their cognitive function through out a certain 
research period, and it is believed that the non-pharmacological treatment played an 
influential role in achieving the stability in cognition and managing the emotional state at 
an affordable cost (11). In the cases where noticeable improvements for the AD patients 
were not apparent, researchers noted that the caregivers claimed a positive impact on the 
quality of their own lives. Although the extent of the effects on the patients is not fully 
clear, other research notes that non-pharmacological interventions such as CT are 
important because there is strong evidence that both the caregivers and mild dementia 
AD patients can receive additional benefits on top of any relief that may be provided by 
pharmacological treatments. 
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VI. Conclusion 
Alzheimer’s disease was first recognized over a century ago, yet the illness continues to 
be a serious detriment to patients and caregivers alike. Despite efforts in research and 
major scientific advancements, a permanent and effective pharmacological cure does not 
exist. Moreover, a precise and comprehensive understanding of AD’s etiopathogenesis is 
unavailable. The major aim of this work is to describe the current literature on the non-
pharmacological interventions for the disease and to evaluate the options that may 
provide the greatest relief and health benefits for the patients. It is also important to 
acknolwedge the difficult responsibilities and struggles of those who provide care for a 
family member or a friend suffering from AD.  
While the idea of exercise has long been proven to provide health benefits, it is important 
to consider the context in which the AD patient is receiving the exercise intervention. AD 
is a pathological condition affecting the older population, and older patients may have an 
inclination towards certain types of exercises. While older adults may favor less 
strenuous aerobic exercises, the literature suggests that anaerobic work may be more 
beneficial in preventing the development or progression of mild cognitive dementia and 
the AD. Participating in exercise types such as progressive resistance training and 
isometric exercise training target anabolic work. These types of exercises are a more 
efficient and effective intervention. Evidence shows that such exercises can directly 
increase levels of cerebral BDNF, which is strongly associated with the promoted 
neuroplasticity, cellular stress resistance, neural growth, and neural protection among 
other benefits. Data also provides evidence that participating in anabolic exercise should 
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be preferred over regular aerobic exercise as such exercises shift APP processing away 
from the non-amyloidogenic. Muscular work can also manage vascular risk factors and 
create a healthy physiological and vascular environment for optimal cerebrovascular 
health. Essentially, the benefits gained by strength exercises cannot be ignored.  
Alzheimer’s disease has a major emotional, psychological, and behavioral toll. Music 
therapy interventions can be evaluated as a necessary component in the care of AD 
patients as they can a create a more well-rounded treatment. Music therapy can take 
various forms such as singing in groups or individually, listening to music, and even 
combining music with dancing. There is significant evidence that music should be 
recommended. Studies show that music promotes neuroplasticity and neurogenesis at the 
physiological level. More importantly, there is widespread agreement that music therapy 
interventions promote positive mood, confidence and strong will among other emotional 
or psychosocial benefits. In the few studies that reported no measurable benefits for the 
patients, it is reported that the caregivers benefitted emotionally as they were able to 
lessen their emotional burden and responsibilities. Music therapy interventions can 
noticeably provide various health and non-tangible improvements for both AD patients 
and their caregivers. Without a doubt, it should be considered for further research to 
provide more lasting and greater positive effects.  
As AD pathogenesis or progression has been associated with systemic and cerebral 
health, it is important for patients to consider diets such as the Mediterranean diet which 
can lead to lower AD risk. A diet high in saturated fatty acid content, processed foods, 
and other factors that are generally incorporated into the standard Western diet is cited to 
 40 
be high risk for AD. A diet that offers abundant healthy fats such as polyunsaturated fatty 
acids and high amounts of vitamin C, folic acid, and sparing uses of spices or herbs such 
as capsaicin are associated with low risk for AD. Vascular risk factors such as 
hypertension and hyperlipidemia are found to promote neuronal damage, apoptosis, 
degeneration, and inflammation. A diet linked to low risk for AD is vital for managing or 
maintaining the cognition of older adults. Family members are highly recommended to 
provide not only emotional care, but also care in the form dietary intervention.  
Cognitive therapy has been rising in popularity as a non-pharmacological intervention for 
mild cognitive impairment and AD. However, it appears that the cognitive improvement 
is more modest, and it might be important to consider whether cognitive therapy 
intervention is a cost-effective option. However, some types psychostimulation program 
combined with pharmacological treatments appear to play an influential role in achieving 
cognitive stability and emotional management.  
Further research is needed in order to improve current non-pharmacological interventions 
that are available for AD patients. The above forms of treatments are available at 
affordable prices and can be incorporated easily into the lifestyles of AD patients. 
Without a doubt, continued research in incorporating these non-drug interventions to the 
overall treatment is an essential component of creating better quality of life for all 
patients and family members suffering from Alzheimer’s disease. 
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